

derivative thereof.

#### REMARKS

Applicants have amended the specification to recite a cross-reference to United States patent application 09/731,129, International patent application PCT/US99/13744 and United States provisional patent application 60/090,094.

Applicants have canceled claims 3, 5-12, 14, 23 and 24 without prejudice. Consistent with this amendment, applicants have amended claims 17, 18 and 20 to recite proper claim dependency.

Applicants have amended claim 22 to delete improper multiple claim dependency. Applicants have added claim 25 to recite the subject matter canceled from amended claim 22. Support for added claim 25 is found in original claim 22.

To more particularly define the present invention, applicants have added claim 26 directed to a method of inhibiting aspartyl protease, and claim 27 directed to a method of treating diseases associated with HIV infections, using the claimed compounds. Support for added claim 26 is found throughout the specification, particularly at page 50, lines 16-18. Support for added claim 27 is found at page 62, lines 1-9 of the specification as originally filed.

None of these amendments adds no new matter.

Applicants request consideration of the  
application and early allowance of the pending claims.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Min Wang (Reg. No. 51,303)

Agent for Applicants

c/o FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090